`U.S. Patent 10,335,462
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner
`
`v.
`NOVO NORDISK A/S,
`Patent Owner
`______________________
`Case IPR2023-00724
`Patent 10,335,462
`______________________
`
`DECLARATION OF DEVRAJ CHAKRAVARTY
`
`
`
`
`
`
`
`
`
`
`Novo Nordisk Exhibit 2049
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00001
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`I, Devraj Chakravarty, hereby declare under penalty of perjury:
`
`1.
`
`I am an Associate Director, Regulatory Affairs at Novo Nordisk Inc.1
`
`Except as otherwise indicated, I have personal knowledge of the facts set forth in
`
`this Declaration. All statements herein made of my own knowledge are true and all
`
`statements made on information and belief are believed to be true. If called upon to
`
`do so, I would testify competently thereto.
`
`2.
`
`EX2048 is a true and correct copy of a document titled Drug Product
`
`Semaglutide B, 1.34 mg/ml, Description and Composition of the Drug Product,
`
`dated June 6, 2014. This document accurately reflects the formulation (which we
`
`refer to as “Semaglutide B”) that was used in the clinical trials for SUSTAIN 6 and
`
`FLOW trials for the 1.0 mg dosage. This is the same formulation used for Novo
`
`Nordisk’s commercial product Ozempic®. This document was stored in Novo
`
`Nordisk’s regulatory files. This document was made and kept in the regular and
`
`ordinary course of Novo Nordisk’s business, at or near the date appearing on the
`
`
`
` Novo Nordisk Inc. is a privately held corporation wholly owned by Novo Nordisk
`
` 1
`
`Commercial Holdings, Inc. Novo Nordisk Commercial Holdings, Inc. is wholly
`
`owned by Novo Nordisk US Holdings Inc. Novo Nordisk US Holdings Inc. is a
`
`privately held corporation wholly owned by Novo Nordisk A/S.
`
`2
`
`Novo Nordisk Exhibit 2049
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00002
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`document (June 6, 2014), and was made by persons with knowledge of the facts and
`
`opinions stated therein.
`
`
`I have been warned that willful false statements and the like are punishable by fine
`
`or imprisonment, or both (18 U.S.C. 1001) and may jeopardize the validity of the
`
`patent at issue in this proceeding. I declare under penalty of perjury that the forego-
`
`ing is true and correct.
`
`
`
`Executed on January 17, 2024 at Plainsboro, New Jersey.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Devraj Chakravarty/
`
`Devraj Chakravarty
`
`3
`
`Novo Nordisk Exhibit 2049
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00003
`
`